Mary Ann Gray receives 4,956-share equity grant at RAPT Therapeutics (RAPT)

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

RAPT Therapeutics director Mary Ann Gray received an annual equity grant. On 01/30/2026 she was awarded 4,956 shares of common stock at a grant price of $0, reported as stock under the company’s non-employee director compensation policy.

The award represents 4,956 restricted stock units that fully vest on the first anniversary of the grant date. Each RSU converts into one share of RAPT Therapeutics common stock upon vesting, aligning director compensation with shareholder equity performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GRAY MARY ANN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,956	$0.00	--

Holdings After Transaction: Common Stock — 4,956 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/02/2026 - 05:53 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRAY MARY ANN

(Last)

(First)

(Middle)

C/O RAPT THERAPEUTICS, INC.

561 ECCLES AVENUE

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	01/30/2026		A		4,956	A	$0	4,956	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.

	/s/ Rodney Young, Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did RAPT (RAPT) report for director Mary Ann Gray?

RAPT reported that director Mary Ann Gray received 4,956 shares on 01/30/2026. The transaction was an equity grant at a price of $0 under the non-employee director compensation policy, reflected as directly owned common stock following the grant.

How many RAPT Therapeutics shares were granted to Mary Ann Gray in this Form 4?

Mary Ann Gray was granted 4,956 shares of RAPT Therapeutics common stock. The grant is tied to restricted stock units under the company’s Amended & Restated Non-Employee Director Compensation Policy and is reported as directly owned after the transaction.

What type of award did the RAPT (RAPT) director receive in this Form 4 filing?

The director received an annual grant of restricted stock units representing 4,956 shares of common stock. These RSUs are issued under RAPT’s Amended & Restated Non-Employee Director Compensation Policy and are structured to vest fully one year after the grant date.

When do Mary Ann Gray’s RAPT restricted stock units vest?

The restricted stock units granted to Mary Ann Gray fully vest on the first anniversary of the grant date. Upon vesting, each RSU entitles her to receive one share of RAPT Therapeutics common stock, as described in the company’s director compensation policy.

What is the exercise or purchase price of the RAPT shares granted to Mary Ann Gray?

The Form 4 reports a transaction price per share of $0 for the 4,956 shares. This reflects that the grant is part of RAPT’s non-employee director compensation rather than an open-market purchase, consistent with typical restricted stock unit awards.

How many RAPT shares does Mary Ann Gray own after this reported transaction?

After the reported grant, Mary Ann Gray is shown as beneficially owning 4,956 shares of RAPT common stock. The shares are held directly and correspond to the restricted stock unit award disclosed in the Form 4 insider transaction table.